CDH2 Antibody

What is CDH2 and why is it significant in research?

CDH2 (Cadherin 2), also known as N-cadherin, is a 99.8-130 kDa type I membrane protein belonging to the cadherin superfamily of calcium-dependent adhesion molecules. It is critically involved in multiple biological processes including embryonic development, cell migration, maintenance of epithelial integrity, synaptogenesis, and establishment of left-right asymmetry in development . Recent research has implicated CDH2 in various pathological processes, including prostate cancer progression, attention-deficit hyperactivity disorder (ADHD), and congenital defects involving cardiac, ocular, and neurological systems . The significance of CDH2 in these diverse processes makes it an important research target across multiple fields including neuroscience, oncology, and developmental biology.

How do I select the appropriate anti-CDH2 antibody for my specific research application?

Selection of the appropriate anti-CDH2 antibody should be based on several critical factors:

• Target epitope consideration: Determine whether you need antibodies targeting the extracellular domain (ECD), intracellular domain, or specific regions within these domains. For instance, if studying receptor shedding processes, antibodies targeting different epitopes of the ECD may be required .

• Application compatibility: Verify validated applications for each antibody. Current literature shows anti-CDH2 antibodies with various validated applications:

• Species reactivity: Ensure cross-reactivity with your experimental model. Most antibodies show reactivity to human, mouse and rat CDH2, though some are specifically validated for zebrafish models .

• Clonality considerations: Monoclonal antibodies (e.g., clones 8C11, 5D5, 13A9, 691721R) offer consistency but limited epitope recognition, while polyclonal antibodies provide broader epitope recognition but potential batch variations .

What controls should I include when using CDH2 antibodies in my experiments?

Proper experimental controls are essential for meaningful CDH2 antibody studies:

Required controls:

• Positive control tissues/cells: Use tissues/cell lines with well-documented CDH2 expression (e.g., neural tissues, specific cancer cell lines)

• Negative control tissues/cells: Include samples known to lack CDH2 expression

• Isotype controls: For flow cytometry and IHC applications, include appropriate isotype-matched control antibodies

• Technical controls: Secondary-only controls to assess non-specific binding

Advanced controls:

• Genetic knockdown/knockout validation: Include CDH2 siRNA/CRISPR-modified samples to confirm specificity

• Peptide competition: Pre-incubation of antibody with immunizing peptide should abolish specific signal

• Multiple antibody validation: Use antibodies recognizing different epitopes to confirm findings

• Recombinant protein controls: Use purified CDH2 protein as standards for quantitative applications

How should I optimize immunohistochemistry protocols for CDH2 detection in different tissue types?

Optimizing IHC protocols for CDH2 detection requires attention to several tissue-specific considerations:

• Antigen retrieval methods: CDH2 epitopes often require heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Compare both methods for your tissue type.

• Tissue-specific considerations:

  • Neural tissues: Require gentle fixation (4% PFA, <24 hours) to preserve membrane localization

  • Cardiac tissues: Often benefit from extended antigen retrieval due to dense tissue architecture

  • Tumor samples: May show heterogeneous expression requiring careful titration of antibody

• Signal amplification: For tissues with lower CDH2 expression, consider:

  • Tyramide signal amplification systems

  • Polymer-based detection systems

  • Extended primary antibody incubation (overnight at 4°C)

• Multiplexing strategies: When co-localizing CDH2 with other markers:

  • Select antibodies raised in different host species

  • Consider sequential immunostaining for challenging combinations

  • Use spectral unmixing for fluorescent applications to resolve overlapping signals

• Optimal antibody dilutions: Most anti-CDH2 antibodies perform optimally at dilutions between 1:50-1:200 for IHC applications, but this requires empirical determination for each tissue type .

How do I address inconsistent or unexpected results when using CDH2 antibodies?

Inconsistent results with CDH2 antibodies may arise from several sources:

• Epitope masking issues: N-cadherin can undergo proteolytic processing by multiple enzymes including ADAM10, MMPs, γ-secretase, and calpain, potentially masking epitopes. If inconsistent results occur:

  • Use antibodies targeting different domains

  • Consider the physiological state of your samples (processing may be biologically relevant)

  • Include protease inhibitors in sample preparation buffers

• Post-translational modification interference:

  • Phosphorylation and glycosylation can affect antibody binding

  • Consider dephosphorylation or deglycosylation treatments as controls

  • Note that CDH2 is expressed as a 130 kDa mature protein, but may appear at different molecular weights due to processing

• Technical troubleshooting table:

• Batch variation considerations: Document lot numbers and compare performance between antibody batches from the same supplier .

How should I interpret differential CDH2 expression patterns in normal versus pathological tissues?

Interpretation of CDH2 expression patterns requires careful consideration of context:

• Normal expression patterns:

  • Predominantly expressed at excitatory synapses in mature neural tissues

  • Present during cardiac development and in adult cardiac tissues

  • Expressed in developing cartilage and bone

• Pathological considerations:

  • Cancer progression: Increased N-cadherin expression is often associated with epithelial-to-mesenchymal transition (EMT) and increased invasiveness. In prostate cancer, increased CDH2 correlates with castration resistance .

  • Neurological disorders: In ADHD models, CDH2 mutations affect synaptic vesicle clustering and transmitter release .

  • Developmental disorders: CDH2 variants are associated with corpus callosum agenesis, cardiac defects, and ocular abnormalities .

• Quantification approaches:

  • For membrane proteins like CDH2, assess both intensity and localization patterns

  • Distinguish between membrane-localized and cytoplasmic/nuclear expression

  • Consider automated image analysis for objective quantification

  • Report both percentage of positive cells and intensity scores for comprehensive analysis

How can I effectively use CDH2 antibodies in live-cell imaging applications?

Live-cell imaging with CDH2 antibodies requires specialized approaches:

• Antibody fragment generation: Convert full IgG antibodies to Fab fragments to reduce crosslinking and internalization:

  • Use commercial fragmentation kits with pepsin or papain digestion

  • Purify fragments using protein A/G columns to remove Fc portions

  • Validate fragment specificity before extensive use

• Site-specific conjugation strategies:

  • Direct conjugation to bright, photostable fluorophores (Alexa Fluor 488, 647)

  • Consider quantum dots for extended imaging

  • Validate that conjugation doesn't impair binding

• Non-perturbing labeling strategies:

  • Target the extracellular domain using antibodies that don't interfere with adhesion function

  • Use pulse-chase approaches to monitor surface dynamics

  • Consider antibodies targeting specific extracellular domains (EC1-5) depending on research question

• Advanced microscopy compatibility:

  • For super-resolution approaches, ensure fluorophore selection is compatible with technique (STORM, PALM, STED)

  • For FRET applications, carefully select donor/acceptor pairs and control for orientation

What are the current approaches for studying CDH2 in therapeutic development research?

Current therapeutic approaches targeting CDH2 include:

• Blocking antibody strategies: Anti-CDH2 antibodies have shown promise in:

  • Inhibiting tumor progression and metastasis in prostate cancer models

  • Delaying emergence of castration resistance

  • Reducing invasiveness of cancer cells

• Experimental design considerations:

  • Control for antibody isotype effects

  • Include pharmacokinetic assessments

  • Evaluate on-target and off-target effects thoroughly

• Combined biomarker applications:

  • Using anti-CDH2 antibodies to identify patients likely to respond to specific therapies

  • Monitoring treatment response through assessment of CDH2 expression patterns

  • Developing companion diagnostics for CDH2-targeting therapeutics

• Toxicity considerations:

  • Monitor for effects on normal tissues with high CDH2 expression (neural, cardiac)

  • Design antibodies with tumor-specific binding characteristics

  • Consider tissue-specific delivery approaches

How are CRISPR/Cas9 technologies being integrated with CDH2 antibody applications in current research?

CRISPR/Cas9 technology is being integrated with CDH2 antibody applications in several innovative ways:

• Validation approaches:

  • Generation of CRISPR knockout cell lines as definitive negative controls for antibody specificity

  • Creation of epitope-tagged CDH2 knock-in models for antibody-independent detection

  • Development of domain-specific mutations to map antibody binding sites

• Functional studies:

  • Introduction of human CDH2 mutations (like H150Y) in mouse models to study pathophysiological mechanisms

  • Analysis of CDH2-dependent phenotypes using antibodies to assess protein expression and localization

  • Creation of conditional CDH2 knockout models to study tissue-specific functions

• Advanced screening applications:

  • CRISPR activation/inhibition libraries to identify regulators of CDH2 expression

  • Antibody-based high-content screens of CRISPR-modified cells

  • Synthetic lethality screens in CDH2-mutant backgrounds

What are the latest developments in quantitative analysis of CDH2 in single-cell studies?

Recent advances in single-cell analysis of CDH2 include:

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated anti-CDH2 antibodies enable multiplexed analysis with >40 parameters

  • Integration with cell cycle markers and signaling pathway components

  • Tissue-based mass cytometry (Imaging Mass Cytometry) for spatial information

• Single-cell multiomics integration:

  • Combining CDH2 protein detection with transcriptomic analysis (CITE-seq)

  • Correlation of CDH2 protein levels with mRNA expression to study post-transcriptional regulation

  • Integration with epigenetic profiling to understand regulatory mechanisms

• Microfluidic approaches:

  • Antibody-based capture of CDH2-positive cells for downstream analysis

  • On-chip assessment of CDH2-mediated cell-cell adhesion dynamics

  • Single-cell western blotting for quantitative protein analysis

• Spatial transcriptomics integration:

  • Combining CDH2 antibody staining with spatial transcriptomics

  • Mapping heterogeneity of CDH2 expression in tumor microenvironments

  • Analysis of CDH2-dependent intercellular communication networks

How should I approach detecting CDH2 in different cellular compartments and processing states?

Detection of CDH2 in different cellular compartments requires consideration of processing states:

• Cellular localization considerations:

  • Full-length CDH2 (130 kDa): Primarily membrane-localized

  • Proteolytically processed forms: Can be found in cytoplasm or nucleus

  • Pro-domain containing precursor: Primarily in Golgi/ER compartments

• Methodological approach by compartment:

• Processing-state specific detection:

  • ADAM10-cleaved fragment detection: ~90 kDa N-terminal fragment, ~40 kDa C-terminal fragment

  • γ-Secretase processed forms: Further C-terminal processing yielding nuclear-targeted fragments

  • MMP-processed forms: Various sized fragments depending on specific MMP

What considerations should be made when studying CDH2 in different model organisms?

Working with CDH2 across different model organisms requires consideration of evolutionary conservation and technical compatibility:

• Cross-reactivity validation table:

• Development-specific considerations:

  • Embryonic expression patterns differ across species

  • Temporal regulation varies – check developmental stage carefully

  • Consider tissue-specific isoforms when selecting antibodies

• Advanced genetic models:

  • CRISPR-modified organisms expressing tagged CDH2 can simplify detection

  • Patient-derived mutations can be introduced in model organisms to study pathophysiology

  • Conditional/inducible models allow temporal control of CDH2 manipulation

By implementing these technical approaches and experimental design strategies, researchers can maximize the utility of CDH2 antibodies in advancing our understanding of this crucial adhesion molecule in normal development and disease states.